Ga-PSMA PET/CT is more accurate for PCa restaging than other currently used PET radiotracers.
The correlations among 68 Ga-PSMA PET/CT, Choline PET/CT, clinical tumor variables and hormonal therapy are extremely important in order to understand the appropriateness of these imaging modalities in prostate cancer patients.
Clinical features, such as clinical stage, PSA level and Gleason score are usually used for the stratification of the prognosis and therapeutic management of prostate cancer patients. Advanced clinical stage and high Gleason score are associated with a poor prognosis, requiring an aggressive and combined treatments. However, data in literature about the correlation between Gleason Score with Choline PET/ CT are controversial. In the study by Cimitan et al. [2] , a significant correlation between the detection rate of 18 FCholine PET/CT in accordance with the Gleason score was found, particularly in patients with low PSA levels. Conversely, Giovacchini et al. [3] did not find any correlation between 11 C-Choline positivity and Gleason score, at multivariate analysis. Similarly, any correlation between the tumor differentiation and 68
Ga-PSMA has been demonstrated [4, 5] . As reported by Meller et al. [6] and Hope et al. [7] , the degree of PSMA up-regulation increases with: (1) increasing primary aggressiveness, (2) the appearance of metastases, (3) testosterone withdrawal, by introducing the androgen deprivation therapy (ADT), and (4) transition to castrate resistant status. The introduction of ADT, by increasing the uptake of PSMA, can be considered an advantage and a disadvantage. The advantage is represented by the ability of PSMA PET/CT to recognize more lesions, conversely the disadvantage is the risk of a disease over-stage due to the "flare-phenomenon effect". However, the different biological behavior of Choline and PSMA for ADT raises some comments: (1) choline metabolism is reduced by ADT, probably due to the under-stimulation of the prostate cancer cells, (2) PSMA receptors are increased in case of missing testosterone, probably due to an up-regulation of the receptors, (3) the availability of diverse hormonal therapies (i.e. LH-RH agonists and antagonists; abirateron acetate and enzalutamide) requires further evaluation of these biological effects.
In the study by Caroli et al. [1] , the detection rate of 68
Ga-PSMA PET/CT was 62.7% in 314 patients with a PSA value, after primary treatments, ranging between 0.03 and 80 ng/mL. In the study by Chondroggianis et al. [8] , in 325 patients undergoing 18 F-Choline PET/CT with a PSA ranging between 0.5 and 80 ng/mL, detection average was 58.2%, with a highend value of 70.5% in patients undergoing ADT and 48.9% in patients who did not undergo ADT. The slight difference Ga-PSMA (about 5%) poses some questions about the interchangeability of the radiopharmaceutical agents, particularly for higher PSA levels. However, also Choline showed an increased uptake in castrate resistant condition, with a higher detection rate (increase of about 22%). Nevertheless, similar data are now missing for PSMA.
The final PSA value identified by Caroli et al. [1] for the identification of positive 68 Ga-PSMA PET/CT was 1.062 ng/ mL, similar to the cut-off value reported for Choline PET/CT [9, 10] . However, as clearly stated by the authors, patients with a PSA value <2 ng/mL and with a GS > 7 and a negative Choline PET/CT would have a positive 68 Ga-PSMA PET/CT in 57 and 81% of cases, although the correlation between PSMA with Gleason score was poor [4, 5] . Again, some questions and new data are necessary in order to understand the exact relationship between the aggressiveness of prostate cancer and expression of PSMA. Probably, the presence of low PSA values (< 2 ng/mL) in patients with an undifferentiated disease (GS > 7) and a castrate-resistant prostate cancer represent the condition for the PSMA expression. Also, Choline PET has demonstrated a higher detection rate for patients with low PSA levels and high Gleason score (>7), reaching a value of 46%, but PSMA seems more promising in these subsets of patients. However, aggressive primary tumors with a Gleason Score > 7 tend to display high 18 F-FDG uptake [11] . An headto-head comparison between 18 F-FDG and 68 Ga-PSMA PET/ CT in this category of patients would be of interest.
Like in the majority of published papers, detection rate cannot be considered like the diagnostic performance, in terms of sensitivity and specificity. In fact, detection rate suggests the presence of a higher radiopharmaceutical uptake in some sites more than the target-tissues, independently from the morphological changes. Specifically, PSMA expression has been found in different benign and pathological conditions and also in autonomic nervous system. Therefore, as for the other radiopharmaceutical agent, the interpretation of PSMA imaging should be carefully made, as suggested by Fanti et al. [12] ; however, a great attention to the history of patients remains essential. From our preliminary experience, we found that also the preparation of patients who are scheduled for 18 F-Choline PET/CT is important. In fact, we found that a prolonged fasting period was associated with higher values of true events than a short period (>10 h vs. 0-5 h) [13] . Thereafter, again, Choline PET/CT is a metabolic imaging, while PSMA provides receptor information, thus not being affected by the fasting.
Most of the cited papers in the study by Caroli et al. [1] were relative to the detection rate of 11 C-Choline PET/CT. In the recent meta-analysis by von Eyben et al. [14] , the authors found that, although not statistically significant, the detection rate of Ga-PSMA reported a higher detection rate for 68 Ga-PSMA than 18 F-Choline for a PSA level which ranged between 0.5 and 2 ng/mL (71% vs. 36%). Interestingly, the majority of patients (n = 27; 76%) had an aggressive disease (high risk based on the European Association guidelines). No data about the concomitant administration of ADT was reported in this study [15] .
Careful analysis of the paper by Caroli et al. [1] raises some comments and opens the door for new discoveries. First, 68 Ga-PSMA is more efficient than Choline PET/CT in patients with an early recurrence of disease (PSA > 0.2 ng/mL), independently from the Gleason score, but especially in the castrate resistant condition. Second, PSMA and Choline have different mechanisms of action and, therefore, cannot be considered interchangeably; however, they should be considered complimentary in some clinical conditions (i.e high PSA levels and well/differentiated tumors). Finally, the key message is that the choice of the nuclear medicine imaging for prostate cancer should arrive from the patient clinical history and from a strong collaboration with the clinicians.
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